High-risk myeloma: a gene expression based risk-st...[Blood. 2008] - PubMed Result

Search for

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Blood. 2008 Jan 15;111(2):968-9. Links

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B.

PMID: 18182586 [PubMed - indexed for MEDLINE]

PMCID: PMC2200846 [Available on 01/15/09]

Related Articles

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. [Blood. 2007]
Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events. [Blood. 2007]
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. [N Engl J Med. 2005]
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. [Br J Haematol. 2007]
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. [Leuk Lymphoma. 2005]
» See all Related Articles...

Patient Drug Information

Bortezomib (Velcade®) Bortezomib is used to treat people with multiple myeloma (a type of cancer of the bone marrow) who have already been treated with at least one other medication. Bortezomib is also used to treat people with mantle cell ly...

» read more ...

Display Show